VEGFR2、p53在非小细胞肺癌中的表达及其与临床特征和化疗疗效的相关性

Expressions of VEGFR2 and p53 and their relationship with clinical characteristics and chemotherapeutic response in non-small cell lung cancer

目的观察血管内皮生长因子受体2(VEGFR2)和p53在非小细胞肺癌(NSCLC)中的表达,并分析其与临床特征和化疗疗效的相关性。方法应用免疫组化染色法检测158例NSCLC组织中VEGFR2和p53的表达情况。收集患者的性别、年龄、吸烟史、病理类型、肿瘤大小、区域淋巴结转移、远处转移、临床分期、肿瘤标志物和近期疗效等临床资料,分析其与VEGFR2和p53的相关性。结果VEGFR2和p53在NSCLC中的高表达率分别为38.6%、23.4%,两者在不同病理类型NSCLC中的表达差异无统计学意义(P>0.05)。VEGFR2在Ⅱ-Ⅵ期患者中的高表达率显著高于Ⅰ期患者(P=0.007);p53在有淋巴结转移、Ⅱ-Ⅵ期患者中的高表达率显著高于无淋巴结转移及Ⅰ期患者(P=0.005,0.002)。VEGFR2高表达患者中p53高表达率明显升高(P=0.000),表明VEGFR2与p53的表达显著相关。接受2周期化疗后,疗效评估为疾病进展的患者VEGFR2高表达率显著高于部分缓解的患者(P=0.040)。结论VEGFR2和p53的高表达与NSCLC的恶性程及化疗敏感性有关,VEGFR2、p53联合检测可能有助于NSCLC患者的个体化治疗。

Objective To observe the expressions of vascular endothelial growth factor receptor 2(VEGFR2)and p53 in non-small cell lung cancer(NSCLC),and analyze their correlation with clinic-pathological factors and chemotherapeutic response.Methods The expressions of VEGFR2 and p53 in 158 cases of NSCLC were detected by immunohistochemical staining method.The information on clinical characteristics including gender,age,smoking status,pathological type,tumor size,regional lymph node metastasis,distant metastasis,clinical stage and treatment was collected,and the associations of VEGFR2 and p53 expressions with clinical characteristics were analyzed.Results The high expression rates of VEGFR2 and p53 in NSCLC tissue samples were 38.6%and 23.4%,respectively.There was no evidence indicating that VEGFR2 and p53 expressions were related to the pathological type.But the high expression rate of VEGFR2 in stageⅡ-Ⅵpatients was significantly higher than in stageⅠpatients(P=0.007),and the high expression rate of p53 in patients with lymph nodes metastases or in stageⅡ-Ⅵwas significantly higher than that of patients with no lymph nodes metastases(P=0.005)or in stageⅠ(P=0.002).VEGFR2 expression was associated with p53 expression,and the rate of patients with high expression of p53 was significantly higher in the group with high VEGFR2 expression than in the group with low VEGFR2 expression(P=0.000).Among the patients after 2 cycles of chemotherapy,the high VEGFR2 expression rate was significantly higher in patients of progressive disease than in those of partial response(P=0.040).Conclusion The high expressions of VEGFR2 and p53 were correlated with the malignant behavior and chemotherapeutic response of NSCLC.Combined detection of VEGFR2 and p53 expression may be helpful for individualized treatment of patients with NSCLC.